Riskpilot← Back to searchSign inGet full accessExeltis Sverige AB
ABActiveOrg 5590131354Arenagatan 35Activities of agents involved in the wholesale of other particular products · NACE 4618Est. 201519 employees
Revenue 2024
SEK 200,4M
+28% vs 2023
EBITDA margin
6.5%
-8% vs 2023
Equity ratio
68.4%
Financial strength
Net profit 2024
SEK 11,4M
-1% vs 2023
| Revenue | SEK 200,4M | +28% |
| EBITDA | SEK 13,1M | -8% |
| Net profit | SEK 11,4M | -1% |
| Total assets | SEK 112,4M | +15% |
| Equity | SEK 76,9M | +17% |
| Employees | 19 | — |
Legal name
Exeltis Sverige AB
Org number
5590131354
Legal form
Aktiebolag
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
7 maj 2015
Share capital
SEK 50 000
Employees
19 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Föremålet för bolagets verksamhet är att importera, distribuera, sälja, marknadsföra och inneha marknadsföringstillstånd för specialistläkemedel och relaterade hälsovårdsprodukter för den nordiska regionen.
Address
Arenagatan 35
Email
isak.lejon@xiromed.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | — | 90 265 | 121 777 | 156 992 | 200 386 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 0 | 11 260 | 8 448 | 14 268 | 13 078 |
| Depreciation & amort. | — | −38 | −121 | −55 | −425 |
| EBIT | 0 | 11 222 | 8 327 | 14 213 | 12 653 |
| Net financials | — | 187 | 2 656 | 2 333 | 1 983 |
| Profit before tax | 0 | 11 409 | 11 007 | 16 563 | 14 636 |
| Tax | — | 10 214 | −2 468 | −5 007 | −3 246 |
| Net profit | — | 21 623 | 8 539 | 11 556 | 11 390 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | — | 64 231 | 81 063 | 98 124 | 112 405 |
| Equity | — | 45 382 | 53 921 | 65 478 | 76 868 |
| Long-term debt | — | 0 | 0 | 0 | 0 |
| Short-term debt | — | 18 849 | 27 141 | 32 646 | 35 537 |
| Total debt | — | 18 849 | 27 141 | 32 646 | 35 537 |
EBITDA margin
6.5%
This company
15.8%
Market median
-59% vs market
20202024
Equity ratio
68.4%
This company
38.2%
Market median
+79% vs market
20202024
Return on equity
14.8%
This company
18.4%
Market median
+20% vs market
20202024
Net profit margin
5.7%
This company
8.1%
Market median
-30% vs market
20202024
Asset turnover
1.78×
This company
1.12×
Market median
+59% vs market
20202024
Debt / equity
0.46×
This company
0.62×
Market median
+26% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
CI Chief Auditor | Chief Auditor | 2022 |
CM Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
GT Chief Auditor | Chief Auditor | 2022 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (2) | ||
| Chairman | 2022 – 2022 | |
| Board of Directors | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EXELTIS PHARMACEUTICALS HOLDING
Exeltis Sverige AB (this company)Board members of Exeltis Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Camilla Iréne Alm Andersson | Chief Auditor | 0 companies |
| Cedric Michel Charroin | Chief Executive Officer | 0 companies |
| Gunvor Therése Henningsson | Chief Auditor | 0 companies |
| Silvia Steyrer-Gruber | Chairman | 0 companies |
| Morán Martín | Board of Directors | 0 companies |
| Piotr Wojczuk | Board of Directors | 0 companies |
| Ignacio Ponce Gutierrez | Chairman | 0 companies |
| Isak Lejon | Board of Directors | 0 companies |